AstraZeneca
rare disease highlights pioneering in rare neurology to improve patient outcomes registry complete terminal complement inhibition patients on low dose after year potential best in class weekly self | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
April 2023
Slide
26 of 41
Related slides by other companies
BenevolentAI
Investor Conference
January 2023
robust pipeline entirely generated by the benevolent platform | BenevolentAI
MP Materials
Investor Conference
May 2022
materials overview our mission is to restore the full rare earth supply chain to the united states years | MP Materials
Faraday Future
SPAC
February 2021
the has already completed most of the vehicle development hurdles a | Faraday Future
Dare Bioscience
Investor Presentation
February 2023
advancing products women want late stage programs cream dare | Dare Bioscience
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights